Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Composition for treating joint disease and kit containing same

a joint disease and joint disease technology, applied in the direction of drug compositions, organic active ingredients, pharmaceutical delivery mechanisms, etc., can solve the problems of short effect duration, relatively large physical burden on the patient, and burden on the patient, and achieve excellent medicinal effects, excellent improvement effect, and reduced burden on the patient

Active Publication Date: 2020-04-30
SEIKAGAKU KOGYO CO LTD
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention aims to provide a composition for treating joint disease that can provide longer-term medicinal effects and reduce the burden on patients. The current anti-inflammatory compounds used in treatment require frequent repeated administration and can be excreted quickly in the body. By using a new composition, it is hoped that this injection can provide better outcomes for patients with chronic joint disease.

Problems solved by technology

In the case of drugs that are administered in the form of relatively invasive injections, the physical burden on the patient is relatively great when the preparation requires continuous administration every one to two weeks.
In the case of injections for single administration, on the contrary, once a dose has been administered the next dose cannot be administered for a certain period of time for insurance reasons.
However, because these anti-inflammatory compounds are metabolized and excreted relatively rapidly in the body, the effect duration is short, and frequent repeated administration is required in order to maintain a sufficient medicinal effect.
Because an injection is a relatively invasive dosage form, frequent repeated administration tends to be burdensome for the patient, and this tendency is particularly strong when a joint disease treatment agent is administered as an injection to a patient suffering from chronic symptoms such as chronic inflammation (in which the pain duration is at least 1.2 weeks for example).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Composition for treating joint disease and kit containing same
  • Composition for treating joint disease and kit containing same
  • Composition for treating joint disease and kit containing same

Examples

Experimental program
Comparison scheme
Effect test

embodiments

[0089]Examples of preferred embodiments of the invention are given below.

[0090][1] A composition for treating joint disease, containing a modified hyaluronic acid or a pharmaceutically acceptable salt thereof having a group derived from a steroidal or non-steroidal anti-inflammatory compound, and is to be used by administration of a single injection to a human joint disease patient once per period of four weeks or more.

[0091][2] The composition according to [1], which is administered the joint disease patient having duration of pain for 26 weeks or more.

[0092][3] The composition according to [1] or [2], which is administered for the joint disease patient having a body mass index (BMI) of at least 25 kg / rm.

[0093][4] The composition according to any one of [1] to [3] wherein the group derived from an anti-inflammatory compound is bonded to hyaluronic acid or a pharmaceutically acceptable salt thereof via a spacer in the modified hyaluronic acid or a pharmaceutically acceptable salt th...

examples

[0141]Preferred embodiments of the invention are explained in detail below with reference to examples, but the scope of the present invention is in no way limited to these examples.

[0142]Unless otherwise specified, operations and measurements of physical properties and the like were performed under conditions of room temperature (not less than 20 C and not more than 25°), not less than 40% and not more than 50% RH.

synthesis examples

[0143]Sodium hyaluronate with introduced aminoethanol-diclofenac (test substance) was synthesized by the methods described in the examples of WO 2005 / 066214 (weight average molecular weight of hyaluronic acid: 800,000, introduction rate: 18 mol %).

[0144]More specifically, this was synthesized by the following procedures.

[0145]2.155 g (10.5 mmol) of 2-bromoethylamine hydrobromide was dissolved in 20 mL of dichloromethane, 1.463 mL (10.5 mmol) of triethylamine was added under ice cooling; and 5 mL of a dichloromethane solution of 2.299 g (10.5 mmol) of di-tert-butyl-dicarbonate (Boc2O) was further added and stirred in. This was stirred for 90 minutes at room temperature, ethyl acetate was added, and the mixture was separately washed successively with 5 wt % aqueous citric acid solution, water, and saturated saline. After dehydration with sodium sulfate, the solvent was distilled off under reduced pressure to obtain Boc-aminoethyl bromide.

[0146]5 mL of a dimethylformamide (DMF) solutio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
weightaaaaaaaaaa
weightaaaaaaaaaa
weightaaaaaaaaaa
Login to View More

Abstract

The present invention pertains to a composition for treating joint diseases and a kit including the same, and the purpose of the present invention is to provide a composition for treating joint diseases which can be used in patients with joint diseases, and a kit which includes the same. The present invention minimizes the burden on patients with chronic joint diseases while also achieving excellent medicinal effects by means of a composition for treating joint diseases which includes a modified hyaluronic acid having a group derived from an anti-inflammatory compound or a pharmaceutically acceptable salt of the modified hyaluronic acid, and which is used by being administered to patients with human joint diseases as a single injection per period of four or more weeks.

Description

TECHNICAL FIELD[0001]The present invention relates to a composition for treating joint disease, and to a kit containing the composition.BACKGROUND ART[0002]As society continues to age, osteoarthritis (hereinafter, also referred to as “OA”), a dysfunction due to joint pain and join degeneration, becomes one of the most common joint disease worldwide, and is one of the principal causes of physical impairment that interferes with daily living in the elderly. Moreover, rheumatoid arthritis (hereinafter, also referred to as “RA”) has been also known as a form of polyarthritis accompanied by joint swelling and pain. In the case of RA, if the disease progress over a long period of time, degeneration or deformation of cartilages and bones may also occur as cartilages and bones are destroyed, restricting the range of joint movement and otherwise causing physical impairment that interferes with daily living.[0003]At present, preparations using hyaluronic acid and its derivatives are used as d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/728A61K9/00A61K31/196A61P19/02
CPCA61K9/0019A61K31/728A61P19/02A61K31/196A61P29/00A61K9/0024A61K9/08
Inventor KANO, KAZUYUKINOBUOKA, YUJISEO, TAKAYUKI
Owner SEIKAGAKU KOGYO CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com